Skip to main content
. 2020 Mar 26;20:245. doi: 10.1186/s12879-020-04959-y

Table 2.

Tuberculosis incidence density stratified by clinical and immunological characteristics of PLHIV on chronic HIV care at Debre-Markos Referral Hospital from January 1, 2014 to December 31, 2018 (N = 494)

Characteristics Frequency (n = 494) Percent (%) Person year TB (n = 62) Censored (n = 432) TB IR per 100 PY
(95% CI)
Past TB treatment
 Yes 14 2.83 36.14 6 8 16.60 (7.46, 36.95)
 No 480 97.17 964.08 56 424 5.81 (4.47, 7.55)
Baseline WHO clinical staging
 Stage I 219 44.33 396.81 7 212 1.77 (0.84, 3.70)
 Stage II 124 25.10 294.67 6 118 2.04 (0.91, 4.53)
 Stage III 122 24.70 263.23 37 85 14.06 (10.18, 19.40)
 Stage IV 29 5.87 45.51 12 17 26.37 (14.97, 46.43)
Baseline CD4 count (cells/μl)
  < 50 38 7.69 79.93 15 23 18.77 (11.31, 31.13)
 50 – < 100 51 10.32 95.09 18 33 18.93 (11.93, 30.04)
 100–200 75 15.18 170.31 14 61 8.22 (4.87, 13.88)
 201–350 123 24.90 268.43 10 113 3.73 (2.00, 6.92)
  ≥ 350 207 41.90 386.46 5 202 1.29 (0.54, 3.11)
Baseline hemoglobin level (g/dl)
  < 10 135 27.33 257.82 52 83 20.17 (15.37, 26.47)
  ≥ 10 359 72.67 742.41 10 349 1.35 (0.72, 2.50)
Baseline body mass index (kg/m2)
  < 18.5 161 32.59 288.03 47 114 16.32 (12.26, 21.72)
  ≥ 18.5 333 67.41 712.19 15 318 2.11 (1.27, 3.49)
Baseline functional status
 Working 392 79.35 832.36 15 377 1.80 (1.09, 2.99)
Ambulate/bedridden 102 20.65 167.86 47 55 28.00 (21.04, 37.27)
Past opportunistic infection (OIs)
 Yes 79 15.99 215.17 18 61 8.37 (5.27,13.28)
 No 415 84.01 785.05 44 371 5.60 (4.17, 7.53)
ART adherence
 Good 367 74.29 763.97 15 352 1.96 (1.18, 3.25)
 Fair/poor 127 25.71 236.25 47 80 19.89 (14.95, 26.48)
Took IPT during follow up
 Yes 195 39.47 406.90 5 190 1.23 (0.51, 2.95)
 No 299 60.53 593.32 57 242 9.61 (7.41, 12.45)
Total year of follow up
  ≤ 1 year 169 34.21 73.98 43 126 58.13 (43.11, 78.37)
  > 1 - < 3 years 180 36.44 353.47 11 169 3.11 (1.72, 5.62)
 3–5 years 145 29.35 572.78 8 137 1.39 (0.69, 2.79)